SLC5A1 and type 2 diabetes mellitus: However, its translational potential will depend on the demonstration of efficacy in chronic T2DM and complication models, the elucidation of its precise SGLT1/2 selectivity profile, comprehensive pharmacokinetic characterization (particularly with oral dosing), and formal toxicology and safety pharmacology studies, including gastrointestinal and cardiovascular assessments.